<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>School of Clinical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F3A0E5EB-ECF7-4DAD-8800-387BFE95A42A"><gtr:id>F3A0E5EB-ECF7-4DAD-8800-387BFE95A42A</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Hart</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F460"><gtr:id>4C6FC017-01D8-4EF4-A45F-779628C48022</gtr:id><gtr:title>Molecular mechanisms and in vivo role of CD44-mediated macrophage phagocytosis of apoptotic neutrophils</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/460</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>593296</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mason Medical Research</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Mason Medical Research Foundation</gtr:fundingOrg><gtr:id>E633E136-F2FB-492C-AD6D-3134D85A2EBE</gtr:id><gtr:outcomeId>JrXgBMrS14A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Yorkshire Cancer Research</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>45C87661-92FA-411C-B771-C30895C6A443</gtr:id><gtr:outcomeId>c1exxB4Pap90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4F4C9DC4-6E3F-402E-9511-487130A45536</gtr:id><gtr:title>Phagocytosis of apoptotic cells.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ab5c7ae2b66a9b258e55a710667f280"><gtr:id>0ab5c7ae2b66a9b258e55a710667f280</gtr:id><gtr:otherNames>Hart SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>LUcUedSkF1B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5DE935C-F3D3-4F37-90F2-2785191F66A3</gtr:id><gtr:title>Stable bronchiectasis is associated with low serum L-ficolin concentrations.</gtr:title><gtr:parentPublicationTitle>The clinical respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40b4645bd44e7554107ddec721ec54f0"><gtr:id>40b4645bd44e7554107ddec721ec54f0</gtr:id><gtr:otherNames>Kilpatrick DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1752-6981</gtr:issn><gtr:outcomeId>WT4UGbCPEd9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15326BC0-5541-4D5B-8600-C2BACD9B10B0</gtr:id><gtr:title>Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>E6MZT2C7o9B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92054D05-52D0-4DCF-B64A-7D16A0D39B54</gtr:id><gtr:title>Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>ptHBWAMpZJi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ECED3CF-F3D8-4BA1-8943-5950114FC3FD</gtr:id><gtr:title>Fc? receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>Lung</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0341-2040</gtr:issn><gtr:outcomeId>caxnfFX1Tw1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22165AAC-CC00-4E80-B0D8-82BC9249FD4C</gtr:id><gtr:title>Analysis of neutrophil apoptosis.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd3a9480697b64a4113ef396de692f16"><gtr:id>bd3a9480697b64a4113ef396de692f16</gtr:id><gtr:otherNames>Taylor EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>TGRHfEg1fsE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBAB1602-46C1-4C8A-A734-0726D1452DF7</gtr:id><gtr:title>Heat-shock protein 60 translocates to the surface of apoptotic cells and differentiated megakaryocytes and stimulates phagocytosis.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c64c8815eec786e3b0671b916f1bfb9"><gtr:id>8c64c8815eec786e3b0671b916f1bfb9</gtr:id><gtr:otherNames>Goh YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>VmXeuE3HSCN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A526C38C-57F7-4962-93D8-90D1234AF794</gtr:id><gtr:title>Characterization of the effects of cross-linking of macrophage CD44 associated with increased phagocytosis of apoptotic PMN.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ab5c7ae2b66a9b258e55a710667f280"><gtr:id>0ab5c7ae2b66a9b258e55a710667f280</gtr:id><gtr:otherNames>Hart SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>563a2d2a757ea1.32834693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C671824A-49F5-418D-943B-D4D24D2A58D4</gtr:id><gtr:title>Functional and clinical consequences of Fc receptor polymorphic and copy number variants.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>sdpaR6nH4gC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D47DD7F-230E-47F3-9601-10AA7C32F453</gtr:id><gtr:title>Choice of anticoagulant critically affects measurement of circulating platelet-leukocyte complexes.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>tDw9vymJ6ux</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>399985D5-AE0B-4C51-BAB3-B58CC6844513</gtr:id><gtr:title>Association of Fc?RIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>563a29051413a8.52696734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FD6F773-9724-426C-999A-D353739ACB31</gtr:id><gtr:title>Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>Respiration; international review of thoracic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b772bfd761ef0f4fbe8e62a534f0f9e"><gtr:id>0b772bfd761ef0f4fbe8e62a534f0f9e</gtr:id><gtr:otherNames>Bournazos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0025-7931</gtr:issn><gtr:outcomeId>563a2904dcc418.75660227</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/460</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>